In a significant move in the realm of AI pathology innovation, Quest Diagnostics, a leading provider of diagnostic information services, has announced a collaboration with PathAI, a renowned entity in AI-powered pathology technology. The association is expected to fast-track the integration of digital and AI pathology, fostering enhanced efficiency in diagnosing diseases like cancer.
Quest Diagnostics Acquires PathAI Diagnostic Assets
As per the definitive agreement, Quest will acquire select assets of PathAI Diagnostics, the division of PathAI that provides anatomic and digital pathology laboratory services. The advanced digitized laboratory of PathAI Diagnostics in Memphis, Tennessee, will transition into Quest’s AI and digital R&D facility. Furthermore, under separate agreements, Quest will secure a license for PathAI’s AISight™, a digital pathology image management system.
Significance of AI and Digital Pathology in Cancer Diagnosis
With AI and digital technologies on its site, Quest aims to significantly improve cancer care. AI pathology innovation plays a crucial role in enhancing the speed and quality of diagnosing cancer and other diseases. With PathAI’s industry-leading expertise, Quest plans to offer high-quality, efficient, and accessible innovations. In addition, the adoption of these technologies will be a major turning point for digital pathology in the U.S.
Expanding the Reach of Diagnostic Services with AI
Digital pathology allows for the creation of digital images of glass slides, facilitating electronic sharing and faster reporting of results. It also extends access to expert consultations to remote areas and addresses the challenge of workforce shortage. Quest’s strategic collaboration with PathAI will enable it to offer flexible digital slide preparation and diagnostic services, both domestically and through its Global Diagnostic Network, overseas.
To conclude, the partnership between Quest Diagnostics and PathAI marks a significant milestone in AI pathology innovation. This strategic alliance has the potential to boost the adoption of digital and AI pathology, improving diagnostic efficiency and quality, particularly in cancer care.
Don’t miss our latest Startup News: Harmonic’s Beacon ISM: A Robust Leap in Broadband Speeds
